'Major vascular events' diaporamas de présentation

Complex Lipid Management

Complex Lipid Management. Tara Dall, MD, FNLA Diplomate, American Board Clinical Lipidology President Advanced Lipidology Delafield, WI www.advlip.com www.lecturepad.org (ongoing clinician education). Disclosures. Speakers Bureau 2012: Abbott, Liposcience, Santarus, HDL labs

814 views • 80 slides

Prevention of Stroke or Recurrent Stroke, Including Management of Risk Factors

Prevention of Stroke or Recurrent Stroke, Including Management of Risk Factors. Evaluation for Cause and Prevention of Stroke Recurrence. Recurrent Stroke. An important outcome for diagnosis and prevention Approximately 25% of the estimated 750,000 strokes each year in the US are recurrences

564 views • 53 slides

The Science: CHD and Diabetes as Co-morbidities

The Science: CHD and Diabetes as Co-morbidities. Kathy Reims, MD Center for Strategic Innovation 8/27/07. Objectives:. What is the rationale to think about diabetes and coronary heart disease (CHD) together? Patient perspective Pathophysiology Treatment

522 views • 44 slides

Results

Results. Preventive therapy in type 2 diabetes: Unresolved issues in 2000. Does standard treatment with fixed combination perindopril/indapamide on top of regular BP control: Produce additional benefits when systolic pressure is lowered below 145 mmHg ?

379 views • 29 slides

Baseline characteristics of HPS participants by prior cerebrovascular disease

Baseline characteristics of HPS participants by prior cerebrovascular disease. Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior cerebrovascular disease. Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior cerebrovascular disease. FACTORIAL TREATMENT COMPARISONS.

356 views • 21 slides

Baseline characteristics of HPS participants by prior cerebrovascular disease

Baseline characteristics of HPS participants by prior cerebrovascular disease. Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior cerebrovascular disease. Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior cerebrovascular disease. FACTORIAL TREATMENT COMPARISONS.

224 views • 21 slides

HPS: Eligibility criteria

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial. UK Medical Research Council ($14M); British Heart Foundation ($2M); Merck ($8M); Roche Vitamins ($8M) Designed , conducted & analysed

249 views • 15 slides

HPS: Eligibility criteria

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial. UK Medical Research Council ($14M); British Heart Foundation ($2M); Merck ($8M); Roche Vitamins ($8M) Designed , conducted & analysed

249 views • 15 slides

Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first

Aspirin for the prevention of recurrent venous thromboembolism (VTE) after a first unprovoked event: results of the ASPIRE randomized controlled trial Brighton T, Eikelboom JW, Mann K, Mister R, Gallus A , Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J

354 views • 15 slides

HPS: Eligibility criteria

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial. UK Medical Research Council ($14M); British Heart Foundation ($2M); Merck ($8M); Roche Vitamins ($8M) Designed , conducted & analysed

159 views • 15 slides

HPS: Eligibility criteria

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial. UK Medical Research Council ($14M); British Heart Foundation ($2M); Merck ($8M); Roche Vitamins ($8M) Designed , conducted & analysed

156 views • 15 slides

Baseline Characteristics by Baseline N-BNP Level

Baseline Characteristics by Baseline N-BNP Level. Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9. Risk of Major Vascular Events, Stroke, Major Coronary Events, and Heart Failure Hospitalization or Death, by Baseline N-BNP Level.

177 views • 6 slides

Delahoy PJ, et al. Clin Ther 2009;31:236-44

Delahoy PJ, et al. Clin Ther 2009;31:236-44. Baseline characteristics and summary of the results of randomized trials of statins (placebo controlled, active controlled, or usual care) that reported clinical outcomes, enrolled >1000 subjects, and followed up for ? 1 year.

146 views • 4 slides

Absolute annual excess risk per 1000 (SE)

209 views • 1 slides

SEARCH

SEARCH. No difference in the incidence of major vascular events between high- vs. low-dose simvastatin, or folate + vitamin B 12 vs. placebo (p > 0.05 for both) No difference in individual outcomes studied

67 views • 1 slides